| Dynacure Adds $55M As RNA-Targeted Muscle Disorder Drug Enters Clinic | Sarah de Crescenzo | 04/03/20 | Boston |
| Fate Inks $100M Deal With Janssen for Stem Cell-Derived Cancer Therapies | Sarah de Crescenzo | 04/03/20 | San Diego |
| Zentalis Upsizes IPO, Raising $165M for Cancer Drug Clinical Trials | Frank Vinluan | 04/03/20 | New York |
| Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More | Sarah de Crescenzo | 04/03/20 | National |
| VenBio Partners Bags $394M to Back More Medicine-Making Biotechs | Sarah de Crescenzo | 04/03/20 | Boston |
| Flagship Adds $1.1B for New Meds, More AI, & “Health Security” | Sarah de Crescenzo | 04/02/20 | National |
| Celularity to Test Natural Killer Cell Therapy for Cancer Against COVID | Sarah de Crescenzo | 04/02/20 | National |
| Iteos Therapeutics Adds $125M to Advance Next-Gen Immunotherapies | Sarah de Crescenzo | 04/02/20 | Boston |
| Vir Advances Antibodies Against COVID-19, CEO Leads BIO’s Coronavirus Outreach | Mandy Jackson | 04/02/20 | National |
| Aspen Neuro Adds $70M to Test Parkinson’s Cell Therapy in the Clinic | Sarah de Crescenzo | 04/01/20 | San Diego |
| Pandion Pulls In $80M as Ulcerative Colitis Drug Advances in Clinic | Frank Vinluan | 04/01/20 | Boston |
| Aptinyx Moves Ahead With PTSD Therapy Study, Pauses 3 Other Trials | Sarah de Crescenzo | 03/31/20 | National |
| A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy | Frank Vinluan | 03/31/20 | Raleigh Durham |
| Tapping Into the Innovation Grid: J&J, Data, and a Shifting Healthcare Focus | Dan Stanton | 03/31/20 | Europe |
| Biohaven’s Acute Migraine Drug Bests Placebo in Prevention Study | Sarah de Crescenzo | 03/30/20 | National |
| Axsome Plans to Try Again After Failure in Treatment-Resistant Depression | Frank Vinluan | 03/30/20 | New York |
| San Diego Biotech Entrepreneurs, Innovation Lead to “Maturing” Ecosystem | Sarah de Crescenzo | 03/30/20 | San Diego |
| Sanofi Adds mRNA COVID-19 Vaccine Bet Through Translate Bio Alliance | Frank Vinluan | 03/27/20 | Europe |
| Equillium Continues Graft-Versus-Host Disease Trial, Pauses 2 Others | Sarah de Crescenzo | 03/27/20 | San Diego |
| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| Forge Inks Roche Deal For Antibiotic Aimed at Drug-Resistant Infections | Sarah de Crescenzo | 03/26/20 | San Diego |
| With $80M, ReCode Looks to Advance RNA Therapies for Lung Diseases | Sarah de Crescenzo | 03/26/20 | San Francisco |
| FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch | Frank Vinluan | 03/26/20 | New York |
| Oncology Needs Combo Therapies & More Data Analysis, Says Bio-Europe Spring Panel | Sarah de Crescenzo | 03/26/20 | Boston |
| Regenacy Pharma Raises $30M for Nerve Function Restoring Treatments | Sarah de Crescenzo | 03/25/20 | Boston |
| AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics | Frank Vinluan | 03/25/20 | Europe |
| Kallyope Gains $112M to Move “Gut-Brain Axis” Programs to the Clinic | Sarah de Crescenzo | 03/25/20 | New York |
| CytomX Lands $80M to Kick Off Cancer Drug R&D Pact With Astellas | Frank Vinluan | 03/24/20 | San Francisco |
| Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing | Brenda Sandburg | 03/24/20 | National |
| Investors Shaken by Coronavirus Sow Seeds of M&A, Financing Slowdown | Sarah de Crescenzo | 03/23/20 | National |
